Table 1.
Summary of the research and development of the CV-A6 vaccine
| Vaccine | Year | Component | Type | CV-A6 strain | CV-A6 | Cell | Stage | Institution | Country | Ref. |
|---|---|---|---|---|---|---|---|---|---|---|
| GenBank ID | /Region | |||||||||
| Monovalent | 2016 | CV-A6 | VLP | SZc173/13 | KF682362.1 | Pichia pastoris | Pre-clinical | Institut Pasteur of Shanghai Chinese Academy of Sciences | Mainland China | [45] |
| Bivalent | 2018 | CV-A6, CV-A10 | INA | / | / | RD | Pre-clinical | Taishan Medical University | Mainland China | [46] |
| Trivalent | 2015 | EV-A71, CV-A16, CA6 | INA | Gdula | AY421764.1 | RD/Vero | Pre-clinical | University of Wisconsin-Madison | United States | [47] |
| 2016 | EV-A71, CV-A16, CA6 | INA | M0746 | / | RD | Pre-clinical | National Health Research Institutes | Taiwan, China | [48] | |
| 2018 | CV-A6, CV-A10, CV-A16 | INA | / | / | RD/Vero | Pre-clinical | National Institute of Health | South Korea | [49] | |
| Quadrivalent | 2018 | EV-A71, CV-A16, CV-A6, CV-A10 | VLP | SZc173/13 | KF682362.1 | Sf9 | Pre-clinical | Institut Pasteur of Shanghai Chinese Academy of Sciences | Mainland China | [50] |
| / | EV-A71, CV-A16, CV-A6, CV-A10 | INA | / | / | / | Pre-clinical | Sinovac Biotech Co., Ltd. | Mainland China | / | |
| / | EV-A71, CV-A16, CV-A6, CV-A10 | INA | / | / | / | Pre-clinical | Wuhan Institute of Biological Products Co., Ltd. | Mainland China | / | |
| / | EV-A71, CV-A16, CV-A6, CV-A10 | INA | / | / | / | Pre-clinical | Minhai Biotechnology Co., Ltd. | Mainland China | / | |
| / | EV-A71, CV-A16, CV-A6, CV-A10 | INA | / | / | / | Pre-clinical | Wantai BioPharm/Xiamen University | Mainland China | / | |
| / | EV-A71, CV-A16, CV-A6, CV-A10 | INA | / | / | / | Pre-clinical | National Vaccine and Serum Institute | Mainland China | / | |
| / | EV-A71, CV-A16, CV-A6, CV-A10 | VLP | / | / | / | Pre-clinical | Huasong (Shanghai) Biomedical Technology Co., Ltd. | Mainland China | / |
INA: Inactivated vaccine. VLP: Virus like particles vaccine. /: Not available.